{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:50:26Z","timestamp":1787878226785,"version":"build-2784847793"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1124\/jpet.120.000301","type":"journal-article","created":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T17:51:31Z","timestamp":1614793891000},"page":"201-206","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Possible Involvement of Muscarinic Receptor Blockade in Mirabegron Therapy for Patients with Overactive Bladder"],"prefix":"10.1016","volume":"377","author":[{"given":"Shizuo","family":"Yamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Chimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Shiho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Okura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Wakuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Shinozuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.120.000301_bib1","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/bph.13367","article-title":"Mirabegron relaxes urethral smooth muscle by a dual mechanism involving \u03b23-adrenoceptor activation and \u03b11-adrenoceptor blockade","volume":"173","author":"Alexandre","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.120.000301_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/nau.22505","article-title":"Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability","volume":"33","author":"Chapple","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/jpet.120.000301_bib3","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00210-015-1128-z","article-title":"\u03b23-Adrenoceptor-mediated relaxation of rat and human urinary bladder: roles of BKCa channels and Rho kinase","volume":"388","author":"Cernecka","year":"2015","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/jpet.120.000301_bib4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejphar.2015.03.074","article-title":"Involvement of \u03b23-adrenoceptors in the inhibitory control of cholinergic activity in human bladder: direct evidence by [(3)H]-acetylcholine release experiments in the isolated detrusor","volume":"758","author":"D\u2019 Agostino","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.120.000301_bib5","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40265-018-0924-4","article-title":"Mirabegron: a review in overactive bladder syndrome","volume":"78","author":"Deeks","year":"2018","journal-title":"Drugs"},{"key":"10.1124\/jpet.120.000301_bib6","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1111\/bph.14121","article-title":"Mirabegron: potential off target effects and uses beyond the bladder","volume":"175","author":"Dehvari","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.120.000301_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40261-012-0031-3","article-title":"Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron","volume":"33","author":"Dickinson","year":"2013","journal-title":"Clin Drug Investig"},{"key":"10.1124\/jpet.120.000301_bib8","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0022-5347(01)61994-3","article-title":"Expression and possible functional role of the beta3-adrenoceptor in human and rat detrusor muscle","volume":"161","author":"Fujimura","year":"1999","journal-title":"J Urol"},{"key":"10.1124\/jpet.120.000301_bib9","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.eururo.2018.05.005","article-title":"Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: a randomised, multicentre phase 3 study (SYNERGY II)","volume":"74","author":"Gratzke","year":"2018","journal-title":"Eur Urol"},{"key":"10.1124\/jpet.120.000301_bib10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s13318-016-0350-5","article-title":"Pharmacokinetic interactions between mirabegron and metformin, warfarin, digoxin or combined oral contraceptives","volume":"42","author":"Groen-Wijnberg","year":"2017","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1124\/jpet.120.000301_bib11","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/bju.13882","article-title":"Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study)","volume":"120","author":"Herschorn","year":"2017","journal-title":"BJU Int"},{"key":"10.1124\/jpet.120.000301_bib12","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1248\/bpb.b16-00194","article-title":"Muscarinic receptor binding in rat bladder urothelium and detrusor muscle by intravesical solifenacin","volume":"39","author":"Ito","year":"2016","journal-title":"Biol Pharm Bull"},{"key":"10.1124\/jpet.120.000301_bib13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1124\/jpet.116.236497","article-title":"Urinary excretion contributed to long-lasting blockade of bladder muscarinic receptors by imidafenacin: effect of bilateral ureteral ligation","volume":"360","author":"Ito","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.120.000301_bib14","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/j.1476-5381.2009.00113.x","article-title":"Quantitative analysis of the loss of muscarinic receptors in various peripheral tissues in M1-M5 receptor single knockout mice","volume":"156","author":"Ito","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.120.000301_bib15","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.eururo.2018.03.020","article-title":"Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis","volume":"74","author":"Kelleher","year":"2018","journal-title":"Eur Urol"},{"key":"10.1124\/jpet.120.000301_bib16","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/j.clinthera.2012.09.010","article-title":"Pharmacokinetic properties of mirabegron, a \u03b23-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women","volume":"34","author":"Krauwinkel","year":"2012","journal-title":"Clin Ther"},{"key":"10.1124\/jpet.120.000301_bib17","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0022-5347(05)00017-0","article-title":"Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder","volume":"175","author":"Maruyama","year":"2006","journal-title":"J Urol"},{"key":"10.1124\/jpet.120.000301_bib18","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.pharmthera.2016.01.007","article-title":"\u03b23-Adrenoceptor agonists for overactive bladder syndrome: role of translational pharmacology in a repositioning clinical drug development project","volume":"159","author":"Michel","year":"2016","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.120.000301_bib19","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1111\/bph.13897","article-title":"The \u03b23 -adrenoceptor agonist mirabegron increases human atrial force through \u03b21 -adrenoceptors: an indirect mechanism?","volume":"174","author":"Mo","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.120.000301_bib20","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/01.ju.0000067621.62736.7c","article-title":"A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders","volume":"170","author":"Nomiya","year":"2003","journal-title":"J Urol"},{"key":"10.1124\/jpet.120.000301_bib21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.molbrainres.2004.09.012","article-title":"Quantitative analysis of binding parameters of [3H]N-methylscopolamine in central nervous system of muscarinic acetylcholine receptor knockout mice","volume":"133","author":"Oki","year":"2005","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1124\/jpet.120.000301_bib22","doi-asserted-by":"crossref","first-page":"F388","DOI":"10.1152\/ajprenal.00392.2016","article-title":"Inhibition of cholinergic neurotransmission by \u03b23-adrenoceptors depends on adenosine release and A1-receptor activation in human and rat urinary bladders","volume":"313","author":"Silva","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/jpet.120.000301_bib23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejphar.2012.11.060","article-title":"The novel \u03b23-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity","volume":"699","author":"Sval\u00f8","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.120.000301_bib24","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1124\/jpet.106.115840","article-title":"Effect of (R)-2-(2-Aminothiazol-4-yl)-4\u2032-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function","volume":"321","author":"Takasu","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.120.000301_bib25","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.3109\/00498254.2012.700140","article-title":"In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective \u03b23-adrenoceptor agonist","volume":"42","author":"Takusagawa","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1124\/jpet.120.000301_bib26","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3109\/00498254.2012.675095","article-title":"Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective \u03b23-adrenoceptor agonist","volume":"42","author":"Takusagawa","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1124\/jpet.120.000301_bib27","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.pharmthera.2018.04.010","article-title":"Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder","volume":"189","author":"Yamada","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.120.000301_bib28","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/iju.13868","article-title":"Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: a multicenter, randomized study in Japan (MILAI II study)","volume":"26","author":"Yamaguchi","year":"2019","journal-title":"Int J Urol"},{"key":"10.1124\/jpet.120.000301_bib29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jphs.2015.05.005","article-title":"The role of muscarinic receptor subtypes on carbachol-induced contraction of normal human detrusor and overactive detrusor associated with benign prostatic hyperplasia","volume":"128","author":"Yamanishi","year":"2015","journal-title":"J Pharmacol Sci"},{"key":"10.1124\/jpet.120.000301_bib30","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.urology.2013.05.017","article-title":"Imidafenacin, an antimuscarinic agent, improves nocturia and reduces nocturnal urine volume","volume":"82","author":"Yokoyama","year":"2013","journal-title":"Urology"},{"key":"10.1124\/jpet.120.000301_bib31","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1254\/jphs.09R14FM","article-title":"The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: bladder selectivity based on in vivo drug-receptor binding characteristics of antimuscarinic agents for treatment of overactive bladder","volume":"112","author":"Yoshida","year":"2010","journal-title":"J Pharmacol Sci"},{"key":"10.1124\/jpet.120.000301_bib32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1254\/jphs.13193FP","article-title":"Muscarinic receptor binding of the novel radioligand, [3h]imidafenacin in the human bladder and parotid gland","volume":"124","author":"Yoshida","year":"2014","journal-title":"J Pharmacol Sci"},{"key":"10.1124\/jpet.120.000301_bib33","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0022-3565(25)09628-4","article-title":"Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins","volume":"273","author":"Wang","year":"1995","journal-title":"J Pharmacol Exp Ther"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524270683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524270683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.120.000301","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T14:02:07Z","timestamp":1739973727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524270683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0022356524270683"],"URL":"https:\/\/doi.org\/10.1124\/jpet.120.000301","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Possible Involvement of Muscarinic Receptor Blockade in Mirabegron Therapy for Patients with Overactive Bladder","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.120.000301","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}